Literature DB >> 28432716

Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells.

J Triñanes1,2, A E Rodriguez-Rodriguez3, Y Brito-Casillas4, A Wagner4, A P J De Vries2, G Cuesto1, A Acebes1, E Salido1,5,6, A Torres1,3,7, E Porrini1.   

Abstract

β Cell transcription factors such as forkhead box protein O1 (FoxO1), v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), pancreatic and duodenal homeobox 1, and neuronal differentiation 1, are dysfunctional in type 2 diabetes mellitus (T2DM). Posttransplant diabetes mellitus resembles T2DM and reflects interaction between pretransplant insulin resistance and immunosuppressants, mainly calcineurin inhibitors (CNIs). We evaluated the effect of tacrolimus (TAC), cyclosporine A (CsA), and metabolic stressors (glucose plus palmitate) on insulinoma β cells in vitro and in pancreata of obese and lean Zucker rats. Cells were cultured for 5 days with 100 μM palmitate and 22 mM glucose; CsA (250 ng/mL) or TAC (15 ng/mL) were added in the last 48 h. Glucose plus palmitate increased nuclear FoxO1 and decreased nuclear MafA. TAC in addition to glucose plus palmitate magnified these changes in nuclear factors, whereas CsA did not. In addition to glucose plus palmitate, both drugs reduced insulin content, and TAC also affected insulin secretion. TAC withdrawal or conversion to CsA restored these changes. Similar results were observed in pancreata of obese animals on CNIs. TAC and CsA, in addition to glucose plus palmitate, induced comparable inhibition of calcineurin and nuclear factor of activated T cells (NFAT); therefore, TAC potentiates glucolipotoxicity in β cells, possibly by sharing common pathways of β cell dysfunction. TAC-induced β cell dysfunction is potentially reversible. Inhibition of the calcineurin-NFAT pathway may contribute to the diabetogenic effect of CNIs but does not explain the stronger effect of TAC compared with CsA.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  animal models; basic (laboratory) research/science; calcineurin inhibitor (CNI); cellular biology; clinical research/practice; diabetes: new onset/posttransplant; drug toxicity; immunosuppressant; islets of Langerhans; kidney transplantation/nephrology; molecular biology

Mesh:

Substances:

Year:  2017        PMID: 28432716     DOI: 10.1111/ajt.14323

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

Review 1.  Post-transplant diabetes mellitus in patients with solid organ transplants.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Endocrinol       Date:  2019-03       Impact factor: 43.330

Review 2.  Prevention of complications from use of conventional immunosuppressants: a critical review.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  J Nephrol       Date:  2019-03-29       Impact factor: 4.393

3.  Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates.

Authors:  Yuanyuan Du; Zhen Liang; Shusen Wang; Dong Sun; Xiaofeng Wang; Soon Yi Liew; Shuaiyao Lu; Shuangshuang Wu; Yong Jiang; Yaqi Wang; Boya Zhang; Wenhai Yu; Zhi Lu; Yue Pu; Yun Zhang; Haiting Long; Shanshan Xiao; Rui Liang; Zhengyuan Zhang; Jingyang Guan; Jinlin Wang; Huixia Ren; Yanling Wei; Jiaxu Zhao; Shicheng Sun; Tengli Liu; Gaofan Meng; Le Wang; Jiabin Gu; Tao Wang; Yinan Liu; Cheng Li; Chao Tang; Zhongyang Shen; Xiaozhong Peng; Hongkui Deng
Journal:  Nat Med       Date:  2022-02-03       Impact factor: 87.241

4.  Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure.

Authors:  Angela Lombardi; Bruno Trimarco; Guido Iaccarino; Gaetano Santulli
Journal:  Cell Commun Signal       Date:  2017-11-13       Impact factor: 5.712

5.  Therapeutic potential of coenzyme Q10 in mitochondrial dysfunction during tacrolimus-induced beta cell injury.

Authors:  Kang Luo; Ji Hyun Yu; Yi Quan; Yoo Jin Shin; Kyung Eun Lee; Hong Lim Kim; Eun Jeong Ko; Byung Ha Chung; Sun Woo Lim; Chul Woo Yang
Journal:  Sci Rep       Date:  2019-05-29       Impact factor: 4.379

Review 6.  Autoimmune Diabetes Recurrence After Pancreas Transplantation: Diagnosis, Management, and Literature Review.

Authors:  María Argente-Pla; Antonio Martínez-Millana; María Isabel Del Olmo-García; Jordi Espí-Reig; Judith Pérez-Rojas; Vicente Traver-Salcedo; Juan Francisco Merino-Torres
Journal:  Ann Transplant       Date:  2019-11-26       Impact factor: 1.530

Review 7.  Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.

Authors:  Manfred Hecking; Adnan Sharif; Kathrin Eller; Trond Jenssen
Journal:  Transpl Int       Date:  2020-11-28       Impact factor: 3.782

Review 8.  Lessons from Human Islet Transplantation Inform Stem Cell-Based Approaches in the Treatment of Diabetes.

Authors:  Taylor M Triolo; Melena D Bellin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-11       Impact factor: 5.555

9.  Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters.

Authors:  Florian Terrec; Thomas Jouve; Hamza Naciri-Bennani; Pierre-Yves Benhamou; Paolo Malvezzi; Benedicte Janbon; Diane Giovannini; Lionel Rostaing; Johan Noble
Journal:  Transplant Direct       Date:  2019-12-24

Review 10.  New-Onset Diabetes after Kidney Transplantation.

Authors:  Claudio Ponticelli; Evaldo Favi; Mariano Ferraresso
Journal:  Medicina (Kaunas)       Date:  2021-03-08       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.